Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Xilio Therapeutics ( (XLO) ) has issued an update.
Xilio Therapeutics has completed a stock purchase agreement with Gilead Sciences, issuing up to $25 million in common stock and prefunded warrants, which will support its ongoing operations and clinical trials. The company’s current cash position, bolstered by the investment, is expected to fund operations until the third quarter of 2025, emphasizing its strategy to advance its tumor-activated immuno-oncology therapies.
More about Xilio Therapeutics
Xilio Therapeutics operates in the biopharmaceutical industry, focusing on developing tumor-activated immuno-oncology therapies. The company’s primary products include vilastobart (XTX101) and XTX301, aimed at treating advanced solid tumors, with a market focus on leveraging the dysregulated biology of tumors to activate therapeutic molecules.
YTD Price Performance: 57.45%
Average Trading Volume: 236,921
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $38.09M
Learn more about XLO stock on TipRanks’ Stock Analysis page.
